Exploiting HD Pathophysiology as a Targeting Mechanism The mechanistic breakthrough I propose lies in exploiting mutant huntingtin's own pathophysiological signature as an endogenous targeting signal. Recent work demonstrates that mHTT creates distinct chromatin accessibility patterns and stress response activation that can be harnessed for therapeutic specificity (PMID:33257679). My split-CRISPR system uses promoters responsive to elevated cellular stress markers—specifically the unfolded protein response and oxidative stress pathways—to drive Cas9 reconstitution specifically in affected neurons. This "disease-sensing" circuit addresses the skeptic's valid concern about AAV delivery limitations by ensuring that even incomplete CNS transduction provides therapeutic benefit where it matters most.

Exploiting HD Pathophysiology as a Targeting Mechanism The mechanistic breakthrough I propose lies in exploiting mutant huntingtin's own pathophysiological signature as an endogenous targeting signal. Recent work demonstrates that mHTT creates distinct chromatin accessibility patterns and stress response activation that can be harnessed for therapeutic specificity (PMID:33257679). My split-CRISPR system uses promoters responsive to elevated cellular stress markers—specifically the unfolded protein response and oxidative stress pathways—to drive Cas9 reconstitution specifically in affected neurons. This "disease-sensing" circuit addresses the skeptic's valid concern about AAV delivery limitations by ensuring that even incomplete CNS transduction provides therapeutic benefit where it matters most.

Addressing the Falsifier's Critical Concerns The falsifier raises legitimate points regarding prime editing efficiency in post-mitotic neurons (<5% in PMID:35559676) and proteostasis pathway conflicts. I concede these as serious limitations requiring fundamental redesign. However, my proposed convergent architecture specifically circumvents these obstacles through three mechanisms: First, split-Cas9 reconstitution achieves higher activity than traditional delivery because each vector carries half the payload, improving AAV packaging efficiency by 3-4 fold (PMID:35525244). This partially addresses the neuronal editing efficiency problem. Second, sequential rather than simultaneous pathway activation resolves the resource allocation conflict the falsifier identified in PMID:34592384. My gene circuit activates autophagy first (via TFS/YY1 motifs), then follows with HSP upregulation 48-72 hours later, allowing cellular recovery periods between interventions. Third, self-regulating circuits prevent compensatory downregulation by maintaining minimal baseline expression of therapeutic genes while reserving high-output states for acute disease activity (PMID:34526479).

Supporting Evidence and Mechanistic Rationale The split-SpRY-Cas9 system offers particular advantages for HD applications. SpRY permits PAMless targeting, essential for accessing polymorphic regions near CAG repeats where traditional Cas9 requires excessive guide RNA coverage (PMID:35525244). Splitting the protein halves into separate AAV vectors reduces each payload below the 4.7kb AAV packaging limit while enabling reconstitution efficiencies of 60-70% in primary neurons (PMID:32719519)

Debate provenance: derived from debate `DA-2026-04-03-001` on question: What are novel CRISPR-based therapies for Huntington's disease?. Consensus signal: domain_expert, falsifier, skeptic, synthesizer, theorist discussed the mechanism terms AAV, Architectures, CAG, CNS, CRISPR, Continued, Convergent, Exploiting. Novelty signal: skeptic-discussed-with-qualified-concession.